Clinical trials: GLP-1
Healthy
The Effect of the Interaction of Glucagon and Insulin on Endogenous Glucose Production in Humans
The purpose of this research is to help understand the relative importance of changes in insulin secretion (which lowers glucose) and changes in glucagon (which raises glucose) to regulate metabolism and the body's ability to…
- Trial name
- NCT04461015
- Testing
- 0.4mU Insulin followed by withdrawal period followed by 0.8mU study, 0.8mU Insulin followed by withdrawal period followed by 0.4mU study
- Where
- United States
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Adrian Vella
Obesity
Effects of Intravenous Infusions of Gut Hormones on Appetite and Metabolism.
The purpose of this study is to investigate the effects of intravenous infusion of two gastrointestinal hormones, PYY3-36 and GLP-1, alone and in combination, on appetite in healthy obese men.
- Trial name
- INGEAR-1 (NCT00940134)
- Testing
- PYY 3-36, GLP-1, saline infusion
- Where
- Denmark
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- University of Copenhagen
Severe Obesity, Type 2 Diabetes Mellitus in Obese
L-Cell Activity in Small Intestine as Biliopancreatic Loop in Obese Patients With DM2 Submitted to RYGBP
Prevalence of Obesity and its association with Diabetes Mellitus 2 (DM2) affect a significant percentage of the world's population with great socioeconomic impact, especially for developing countries.
- Trial name
- NCT05446415
- Testing
- Analyze basal expression incretin for immunolabeling and mRNA expression glucagon-like secretion peptide-1 (GLP-1) and peptide YY (PYY 3-36) incretins by L cells.
- Where
- Brazil
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- University of Sao Paulo General Hospital
Hypoglycemia
Post Bariatric Closed Loop Glucagon Trial
This study is to test our automated hypoglycemia prevention and treatment device (glucagon-only bionic pancreas) in subjects that have undergone post-bariatric surgery that are experiencing symptoms of hypoglycemia.
- Trial name
- NCT02966275
- Testing
- Glucagon-only bionic pancreas - glucagon
- Where
- United States
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- Massachusetts General Hospital
Stage 1 Diabetes Mellitus, Type 1
GLP-1 RA for Stage 1 Type 1 Diabetes
This study seeks to evaluate the hormone responses of insulin, c-peptide, glucagon, and incretins to semaglutide, a GLP-1 receptor agonist therapy, in individuals with stage 1 type 1 diabetes.
- Trial name
- NCT07430332
- Testing
- Semaglutide
- Where
- United States
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- Children's Hospital Medical Center, Cincinnati
Diabetes Mellitus, Type 2, Metabolic Syndrome
Isomaltulose VS Sucrose - Postprandial Effect on Incretin Profile and Second Meal Effect
This study evaluates the different postprandial effect of isomaltulose and sucrose on the incretin profile and as an determinant for the second meal effect.
- Trial name
- NCT03806920
- Testing
- Intervention A, Intervention B, Intervention C
- Where
- Germany
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- German Institute of Human Nutrition
Longevity, Quality of Life
Effectiveness of Microdosed GLP-1 in Improving Health, Quality of Life, and Longevity Measures
The goal of this clinical study has two objectives. The Primary Objective is to evaluate the effectiveness of microdosed GLP-1 receptor agonists in improving measures of health, quality of life, and longevity.
- Conditions
- Longevity, Quality of Life, Mood, Inflammation
- Trial name
- NCT07092605
- Testing
- GLP-1
- Where
- United States
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- AgelessRx
Postprandial Glucose, GLP-1 Concentration
Postprandial Glycemic and GLP-1 Responses to Modified Full-sugar Drinks
This randomized, double-blind, crossover study will evaluate postprandial blood glucose and glucagon-like peptide-1 (GLP-1) responses to different sugar-containing beverages in healthy adults.
- Conditions
- Postprandial Glucose, GLP-1 Concentration, Satiety
- Trial name
- NCT07918196
- Testing
- Sucrose Beverage, Glucose + Fructose beverage, Sucrose with EGCG Beverage
- Where
- United States
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Purdue University
Obesity
A Study in People With Obesity to Test the Effects of BI 456906 Compared With Semaglutide on Glucagon Receptor Activity in the Liver
This study is open to adults with obesity. People with a body mass index (BMI) in the range from 30 to 40 kg/m2 and a body weight of 70 to 150 kg can participate in the study.
- Trial name
- NCT05202353
- Testing
- BI 456906, Semaglutide
- Where
- Netherlands
- Volunteers
- 29 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Type 2 Diabetes, Prediabetes
Seum Bile Acid Profile in Type 2 Diabetes and Association Between Bile Cid Profile and Adipokine or Oxidative Stress
"The goal of this work is to critically test the hypothesis that there exists a different profile of bile acids (BAs) in patient with type 2 diabetes mellitus (T2DM) compared with normal controls.
- Conditions
- Type 2 Diabetes, Prediabetes, Non-alcoholic Fatty Liver Disease, Metabolic Syndrome
- Trial name
- NCT02650830
- Where
- South Korea
- Volunteers
- 362 people, healthy volunteers welcome
- Sponsor
- Yonsei University
Hypoglycemia, Hypoglycemia, Reactive
Post-Prandial Carbohydrate Metabolism in Individuals With and Without Post-Bariatric Surgery Hypoglycemia (PBH)
In this study, the investigators will determine (a) whether metabolism (secretion and turnover) of glucagon is altered in patients with PBH, (b) whether this is affected by a meal, (c) whether PBH affects the ability of the body…
- Conditions
- Hypoglycemia, Hypoglycemia, Reactive, Bariatric Surgery
- Trial name
- NCT07818707
- Testing
- Glucagon for Injection (Fresenius Kabi USA), [6,6-2H2] glucose, [13C9, 15N1]-glucagon
- Where
- 2 sites in United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Joslin Diabetes Center
Healthy Volunteers (HV)
A Study of IBI3042 in Healthy Adult Participants
This is a randomized, investigator- and participant-blinded, placebo-controlled, parallel-group, dose-escalation Phase 1 study to evaluate the safety, tolerability, and pharmacokinetics of single ascending oral doses of IBI3042…
- Trial name
- NCT07842393
- Testing
- Investigational Drug: IBI3042
- Where
- United States
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Fortvita Biologics (USA)Inc.
Type 2 Diabetes, Obesity
The Microvascular Function of GLP-1 and Its Analogues
Incretins have become a successful drug target in the repertoire of medications used for the treatment of type 2 diabetes. However little is known about a potential benefit of GLP-1 on the vascular system in humans, independent…
- Trial name
- NCT01677104
- Testing
- GLP-1
- Where
- United Kingdom
- Volunteers
- 63 people, healthy volunteers welcome
- Sponsor
- Katarina Kos
Sleep Deprivation, Sex Differences
Evaluation of Sex Differences in Glucose Metabolism in Response to Sleep Curtailment
The goal of this study is to learn whether insufficient sleep affects glucose metabolism differently in healthy men and women.
- Conditions
- Sleep Deprivation, Sex Differences, Glucose Tolerance
- Trial name
- NCT06809023
- Testing
- Sleep restriction
- Where
- United States
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Brigham and Women's Hospital
Diabetes Mellitus, Type 2, Insulin Resistance
The Aging Endocrine Pancreas: Characterization of the Entero-insular Axis Physiology in the Elderly
Like most endocrine axes, the entero-insular axis is expected to go through an age-related physiological deterioration, what might contribute to special features of the elderly onset type 2 diabetes in comparison to middle-age.
- Trial name
- NCT00843479
- Where
- Brazil
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- University of Campinas, Brazil
Healthy Participants
A Study to Investigate the Pharmacokinetics of Different Formulations and Safety of AZD5004 in Healthy Participants Aged 18 to 55 Years
The purpose of this study is to assess the pharmacokinetics (PK), safety and tolerability of different oral formulations of AZD5004, and to evaluate the effect of food on these formulations in healthy participants.
- Trial name
- NCT07455825
- Testing
- AZD5004
- Where
- 2 sites in United States
- Volunteers
- 65 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
GLP-1, Alcohol
Impact of GLP-1 Receptor Agonist Therapy on Alcohol Pharmacokinetics
This study is to learn how the weight loss drug tirzepatide (Zepbound) changes the way a body handles alcohol. 5 participants aged 21-55 who take Zepbound will be enrolled and can expect to be on study for up to 4 weeks.
- Trial name
- TAP (NCT07758231)
- Testing
- Acute Ethanol Dose
- Where
- United States
- Volunteers
- 5 people, healthy volunteers welcome
- Sponsor
- University of Wisconsin, Madison
Type 2 Diabetes Mellitus, Bone Remodeling
Changes in Bone Turnover With Exposure to a GLP-1 Receptor Agonist
The purpose of this study is to determine changes in bone turnover markers and calcitonin following the initiation of exenatide compared to placebo in postmenopausal women wtih type 2 diabetes.
- Trial name
- CMBD (NCT01381926)
- Testing
- exenatide, Saline
- Where
- United States
- Volunteers
- 14 people, healthy volunteers welcome
- Sponsor
- University of Alabama at Birmingham
Glucagon-Like Peptide-1 Receptor Agonists
HDM1002 Tablets in Chinese Overweight and Obese Adult Subjects
To assess the safety of multiple oral doses of HDM1002 tablets under different titrations in Chinese overweight and obese adult subjects.
- Trial name
- NCT06520540
- Testing
- HDM1002 100 mg QD 12weeks, HDM1002 200 mg QD 12weeks, HDM1002 400 mg QD 12weeks，Q 2W for titration
- Where
- China
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.
Glucose Metabolism Disorders
The Anatomical Location, Cellular Origin and Molecular Basis of Gut-derived Glucagon Secretion
Delineation of the anatomical location, cellular origin and molecular basis of gut-derived glucagon secretion
- Trial name
- NCT03181191
- Testing
- Oral glucose tolerance test
- Where
- Denmark
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- University Hospital, Gentofte, Copenhagen